|
|
WOODLAND招募200名疫苗志愿者，为Novavax进行最后的临床试验！
Dignity Health seeks volunteers at Woodland clinic for Novavax’s COVID-19 vaccine trial
Dignity Health在Woodland诊所为NovavaxCOVID-19疫苗试验寻找志愿者
Dignity Health announced Monday that its clinics in Yolo County will be enrolling 200 patients in a late-stage clinical trial of the COVID-19 vaccine candidate developed by Novavax.
Dignity Health周一宣布，其设在约洛县(Yolo County)的诊所将招募200名患者，对诺瓦瓦克斯(Novavax)开发的COVID-19候选疫苗进行后期临床试验。
The Maryland-based biotech company won attention from both researchers and Wall Street for the impressive number of antibodies its candidate produced in its early testing. The company also is working with UC Davis Health, which is enrolling 200-300 people in the phase 3 clinical trial for the candidate formally known as NVX-CoV2373.
这家总部位于马里兰州的生物技术公司因其候选产品在早期测试中产生的大量抗体而赢得了研究人员和华尔街的关注。该公司还与加州大学戴维斯分校健康中心(UC Davis Health)合作，后者正在招募200-300人参与该候选药物NVX-CoV2373的3期临床试验。
“The COVID-19 pandemic continues to surge, with record number of individuals being infected every day. Continued research is needed in vaccines and treatments to help end the pandemic,” said Dr. Rajan Merchant, a clinical immunology specialist with Dignity’s Woodland clinic. “The development of multiple vaccines will ensure options for patients, creating a larger impact in the fight against coronavirus.”
“COVID-19大流行继续激增，每天被感染的人数创纪录。需要在疫苗和治疗方面继续进行研究，以帮助结束大流行，”Woodland诊所的临床免疫学专家Rajan Merchant博士说。“多种疫苗的开发将确保患者有选择，在抗击冠状病毒的战斗中产生更大的影响。”
Overall, Novavax is seeking roughly 30,000 participants in the United States and Mexico, and it also has late-stage trials going on in the United Kingdom and phase 2 trials in South Africa and Australia. Its phase 1 results were published Sept. 2 by the New England Journal of Medicine.
总的来说，Novavax 正在美国和墨西哥寻找大约3万名参与者，它也在英国进行后期试验，在南非和澳大利亚进行第二阶段试验。其一期研究结果发表在9月2日的《新英格兰医学杂志》上。
The Novavax vaccine has an immune-boosting agent that signals the body to make antibodies to the spike proteins that stud the surface of the new coronavirus, the pathogen that causes COVID-19. That prevents those spike proteins from hooking up to cells within the bodies, hijacking their processes and turning them into virus-producing factories.
Novavax 疫苗含有一种免疫增强剂，可以向身体发出信号，让身体产生针对新型冠状病毒(COVID-19病原体)表面刺突蛋白的抗体。这就阻止了这些刺突蛋白连接到体内的细胞上，劫持它们的过程，把它们变成制造病毒的工厂。
Like the Moderna and Astrazeneca vaccines, the Novavax candidate will be given in two doses administered three weeks apart. As with all the clinical trials, not all patients will receive the vaccine candidate. UC Davis noted that two people will get the vaccine for every person receiving a placebo, and neither the participants nor the researchers will know who gets either.
与Moderna和阿斯利康(Astrazeneca)的疫苗一样，Novavax候选疫苗将分两次注射，间隔3周。与所有临床试验一样，并不是所有患者都将接受候选疫苗。加州大学戴维斯分校指出，每两个人接种一种安慰剂，就会有两人接种疫苗，参与者和研究人员都不知道谁接种了这两种疫苗。
“The [Novavax] vaccine contains protein antigens that cannot replicate or cause COVID-19. The antibodies generated by the vaccine will help protect the body from the real, fully-potent virus,” said Dr. Stuart Cohen, chief of the Division of Infectious Diseases and director of Hospital Epidemiology and Infection Prevention at UC Davis Health.
“疫苗含有不能复制或导致COVID-19的蛋白抗原。由疫苗产生的抗体将有助于保护身体免受真正的、完全有效的病毒的伤害，”斯图尔特·科恩博士说，他是加州大学戴维斯分校传染病科主任和医院流行病学和感染预防主任。
Over the course of the 26-month study, patients will have to return for eight to 10 visits, UC Davis officials noted.
加州大学戴维斯分校的官员指出，在为期26个月的研究过程中，患者将需要返回医院就诊8到10次。
Locally, Dignity is running the Novavax trial through its Woodland Clinic, based at 632 W. Gibson Road, but the health provider also expects to see volunteers from its affiliate offices at 2081 Bronze Star Drive, 1321 Cottonwood St., 515 Fairchild Court and 1207 Fairchild Court in Woodland and at 2330 W. Covell Blvd. and 2440 W. Covell Blvd. in Davis.
在当地，尊严制药公司正在其位于西弗吉尼亚州632号的伍德兰诊所进行诺瓦瓦克斯的试验。吉布森路，但医疗服务提供商也希望看到志愿者从其附属办事处2081青铜星道，1321 Cottonwood街，515 Fairchild Court和1207 Fairchild Court在林地和2330 W。Covell大街上。和2440 W。Covell大街上。在戴维斯。
UCD and Dignity are looking to get a diverse group of patients who represent the ages, ethnic and racial groups and health conditions in the Sacramento population.
UCD和Dignity正在寻找代表萨克拉门托人口年龄、族裔和种族和健康状况的多样化患者群体。
Novavax received a $1.6 billion grant from the U.S. government’s Operation Warp Speed and $388 million from the global Coalition for Epidemic Preparedness Innovations to support its efforts to develop a vaccine. Companies are developing more than 100 COVID-19 vaccine candidates.
Novavax获得了美国政府Operation Warp Speed提供的16亿美元赠款，以及全球流行病防范创新联盟(global Coalition for Epidemic Preparedness Innovations)提供的3.88亿美元赠款，以支持其开发疫苗的努力。这些公司正在开发100多种COVID-19候选疫苗。
联系人:-
电话号码:
|
|
发表于 2021-1-5 08:42:53
发表于 2023-1-7 04:51:04